Nuclear Data Sheets for A=177

Kondev, F. G.

doi:10.1016/j.nds.2019.100514

Cited by 32 publications

(22 citation statements)

References 249 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This code has previously been validated for use in nuclear medicine therapies [ 25 – 27 ]. The radionuclide data were based on the Nuclear Data Sheets of Kondev et al [ 28 ] and are the same as in OLINDA/EXM® [ 29 ]. A CT scan of a Gammex tissue characterization phantom (Gammex 467; Gammex Inc., Middleton, WI) using the same imaging parameters from the patient scans was perfMC method: Patient-specificormed, which confirmed the HU-to-density relationship of our CT device with that implemented in GATE.…”

Section: Methodsmentioning

confidence: 99%

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

et al. 2021

View full text Add to dashboard Cite

Background Patients with metastatic, castration-resistant prostate cancer (mCRPC) present with an increased tumor burden in the skeleton. For these patients, Lutetium-177 (Lu-177) radioligand therapy targeting the prostate-specific membrane antigen (PSMA) has gained increasing interest with promising outcome data. Patient-individualized dosimetry enables improvement of therapy success with the aim of minimizing absorbed dose to organs at risk while maximizing absorbed dose to tumors. Different dosimetric approaches with varying complexity and accuracy exist for this purpose. The Medical Internal Radiation Dose (MIRD) formalism applied to tumors assumes a homogeneous activity distribution in a sphere with unit density for derivation of tumor S values (TSV). Voxel S value (VSV) approaches can account for heterogeneous activities but are simulated for a specific tissue. Full patient-individual Monte Carlo (MC) absorbed dose simulation addresses both, heterogeneous activity and density distributions. Subsequent CT-based density weighting has the potential to overcome the assumption of homogeneous density in the MIRD formalism with TSV and VSV methods, which could be a major limitation for the application in bone metastases with heterogeneous density. The aim of this investigation is a comparison of these methods for bone lesion dosimetry in mCRPC patients receiving Lu-177-PSMA therapy. Results In total, 289 bone lesions in 15 mCRPC patients were analyzed. Percentage difference (PD) of average absorbed dose per lesion compared to MC, averaged over all lesions, was + 14 ± 10% (min: − 21%; max: + 56%) for TSVs. With lesion-individual density weighting using Hounsfield Unit (HU)-to-density conversion on the patient’s CT image, PD was reduced to − 8 ± 1% (min: − 10%; max: − 3%). PD on a voxel level for three-dimensional (3D) voxel-wise dosimetry methods, averaged per lesion, revealed large PDs of + 18 ± 11% (min: − 27%; max: + 58%) for a soft tissue VSV approach compared to MC; after voxel-wise density correction, this was reduced to − 5 ± 1% (min: − 12%; max: − 2%). Conclusion Patient-individual MC absorbed dose simulation is capable to account for heterogeneous densities in bone lesions. Since the computational effort prevents its routine clinical application, TSV or VSV dosimetry approaches are used. This study showed the necessity of lesion-individual density weighting for TSV or VSV in Lu-177-PSMA therapy bone lesion dosimetry.

show abstract

Section: Methodsmentioning

confidence: 99%

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1 Decay branches of 181 Hg and its daughter isotopes. The data are taken from Nuclear Data Sheets [44][45][46] and [47].…”

Section: Methodsmentioning

confidence: 99%

Nuclear structure of $$^{181}$$Au studied via $$\upbeta ^+$$/EC decay of $$^{181}$$Hg at ISOLDE

et al. 2020

View full text Add to dashboard Cite

The β + /EC decay of mass separated samples of 181 Hg was studied employing the TATRA spectrometer at the ISOLDE facility at CERN. The decay scheme was constructed for the first time. A Broad Energy Germanium detector was used to achieve this by combination of high-gain γ-ray singles spectroscopy and γ-γ coincidences. The systematics of excited states associated with the 1h 11/2 proton-hole configuration in odd-Au isotopes was extended.

show abstract

“…177m Lu is a high-energy nuclear isomer with a half-life of 160.4 days. 78.6% of 177m Lu decays by beta emission to 177m Hf and 177 Hf and 21.4% decays to 177 Lu, the ground state, via isomeric transition 13 14 . Isomeric transition can occur either via internal conversion or γ rays emission (see Fig.…”

mentioning

confidence: 99%

Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects

Bhardwaj

Meer

Das

et al. 2017

Sci Rep

View full text Add to dashboard Cite

177Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β− emission results in very efficient energy deposition in small-size tumours. Because of this, 177Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177mLu and 177Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177mLu/177Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177Lu and can bring significant growth in the research and development of 177Lu based pharmaceuticals.

show abstract

Nuclear Data Sheets for A=177

Cited by 32 publications

References 249 publications

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

Nuclear structure of $$^{181}$$Au studied via $$\upbeta ^+$$/EC decay of $$^{181}$$Hg at ISOLDE

Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects

Contact Info

Product

Resources

About